GLP-1 Market
LLY $1179.27 ▲ +0.8% NVO $38.64 ▲ +1.2% PFE $28.28 ▲ +1.7% VKTX $28.51 ▲ +2.8% KLRA $11.61 ▲ +16.1% GPCR $25.54 ▼ -0.5% RHHBY $54.09 ▲ +1.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NIO752

NIO752

Company
Novartis Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for NIO752 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06372821

    A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    Not yet reported University College, London 10 participants Est. completion 2026-07 2 sites Stand-alone
    Other conditions: Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
    View official trial listing →
  • Recruiting NCT NCT07498426

    A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

    Not yet reported Novartis Pharmaceuticals 300 participants Est. completion 2031-07-18 42 sites Stand-alone
    Other conditions: Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
    View official trial listing →
  • Completed NCT NCT04539041

    Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

    Not yet reported Novartis Pharmaceuticals 59 participants Est. completion 2024-10-17 12 sites Stand-alone
    Other conditions: Progressive Supranuclear Palsy (PSP)
    View official trial listing →
  • Active, not recruiting NCT NCT05469360

    Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

    Not yet reported Novartis Pharmaceuticals 38 participants Est. completion 2027-09-24 10 sites Stand-alone
    Other conditions: Alzheimer Disease, Mild Cognitive Impairment
    View official trial listing →
  • Not yet recruiting NCT NCT07868328

    A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

    Not yet reported Novartis Pharmaceuticals 48 participants Est. completion 2030-05-20 Stand-alone
    Other conditions: Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.